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Management of Community-Acquired Pneumonia in Adults
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1. Introduction
Pneumonia is an acute infection of the lung parenchyma distal 
to the terminal bronchiole, most commonly bacterial in nature, 
and associated with clinical and/or radiological evidence of 
consolidation of part or parts of one or both lungs.  It remains a 
cause of considerable morbidity and mortality throughout the 
world.  Mortality is improved by early initiation of antibiotics to 
which the causative organism(s) are susceptible, and adversely 
affected by delayed or inappropriate initial therapy.
2. Aim of the guideline
The main purpose of the guideline is to provide rational and 
cost-effective recommendations regarding choice of initial 
empiric antibiotic therapy that is likely to improve patient 
survival.
3. Categories of community-acquired 
pneumonia (CAP)
This revision of the guideline is presented in recognition of the 
following:
•    Increasing antibiotic resistance among some of the common 
organisms
•    The availability of new antimicrobial agents
•    International trends based on evidence published since the 
previous guideline.
Advice is given for differences associated with age, the 
severity of the infection and the presence or absence of 
underlying/coexistent disorders.  The following categories are 
considered separately:
•    Adults without co-morbid illness
•    The elderly and/or adults with co-morbid illness, including 
concomitant HIV infection,  and
•    Severely ill adults.
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Objective.  To revise the existing South African community-
acquired pneumonia guideline in the light of the following 
factors:
•    Increasing antibiotic resistance
•    Introduction of new antibiotics
•    International trends based on evidence published since the 
previous guideline.
The main aim of the guideline is to recommend an initial 
choice of antibiotics in patients with community-acquired 
pneumonia encompassing the following subgroups:  
•    Adults without co-morbid illness  
•    The elderly and/or those with associated co-morbid 
illness, including patients with concomitant human 
immunodeficiency virus (HIV) infection, and 
•    Patients with severe pneumonia.
Options.  Studies comparing patient outcome obtained with 
the various treatment regimens have been reviewed.  The 
choice of antibiotic is based on the most commonly isolated 
pathogens, with cost as a consideration.
Outcomes.  The empiric antibiotic therapy covers all commonly 
encountered organisms in patients with community-acquired 
pneumonia and is likely to achieve the best prognosis.
Evidence. Working group of clinicians and clinical 
microbiologists, following detailed literature review, 
particularly of studies performed in South Africa.
Benefits, harms and costs.  The guideline pays particular 
attention to cost-effectiveness in South Africa and promotes 
rational antibiotic prescribing with the aim of limiting 
emergence of antibiotic resistance. 
Recommendations.  These include details of likely pathogens, 
an appropriate diagnostic approach, indicators of severity 
of illness, need for hospitalisation and antibiotic treatment 
options.
Validation.  The guideline was updated by a working group of 
the South African Thoracic Society, which included members 
of the Critical Care Society of Southern Africa, and the 
Federation of Infectious Diseases Societies of Southern Africa.  
Reference was made to the recently updated international 
guidelines from the UK, Europe, Canada and the USA.
Endorsement. The guideline is endorsed by the South African 
Thoracic Society, the Federation of Infectious Diseases 
Societies of Southern Africa, and the Critical Care Society of 
Southern Africa.
S Afr Med J 2007; 97: 1295-1306.
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4. Causative organisms in CAP 
4.1  Although many organisms may cause pneumonia, 
relatively few pathogens account for most cases.  The list of 
organisms commonly associated with pneumonia includes:
•    Streptococcus pneumoniae
•    Atypical pathogens
     •    Mycoplasma pneumoniae
     •    Chlamydia pneumoniae
     •    Legionella species
•    Respiratory viruses
•    Haemophilus influenzae
•    Aerobic Gram-negative bacilli (e.g. Klebsiella pneumoniae)
•    Staphylococcus aureus.
4.2  There is uncertainty about the true incidence of so-called 
‘atypical infections’ in patients with pneumonia in South 
Africa.  Infections with organisms such as C. pneumoniae 
and M. pneumoniae are cyclical.  There is geographical 
variation in the incidence of infection with Legionella spp.  
Evidence from academic units in South Africa where the 
prevalence of Legionella infection has been studied suggests 
this to be low.
4.3  Some differences are noted in the various patient categories. 
Patients with chronic obstructive pulmonary disease  
(COPD) may have more infections with H. influenzae.  In 
elderly patients more infections with Gram-negative 
organisms occur.  Severely ill patients are infected more 
frequently with K. pneumoniae and S. aureus.
4.4  Polymicrobial infections are fairly common, especially in 
the elderly and in severely ill patients.
4.5  Infections with anaerobic organisms occur more 
commonly in the elderly and in patients with increased 
risk of aspiration (for example alcoholism, epilepsy, 
cerebrovascular accident).
4.6  In HIV-seropositive patients there is an inverse relationship 
between the CD4 cell count and the frequency of 
pneumonia, but CAP may occur in HIV-seropositive 
patients at any stage of the infection.  Pneumonia is most 
common when the CD4+ count falls below 200 cells/μl.  
The organisms responsible for CAP in HIV-seropositive 
patients are the same as in HIV-seronegative cases.  The 
most common bacterial causes of pneumonia are S. 
pneumoniae and H. influenzae.  Infections with S. aureus and 
aerobic Gram-negative bacilli are also relatively common.  
Unusual causes of CAP are Pseudomonas aeruginosa and 
Rhodococcus equi.  The possibility of infection with an 
opportunistic pathogen, notably Pneumocystis jirovecii, 
always needs to be considered.  Any of these infections may 
occur alone or in combination with more usual bacterial 
pathogens.  The risk of opportunistic infections increases as 
the CD4 cell count falls.
4.7  Risk factors for pseudomonal infections in patients with 
CAP include the following:
•    Patients with structural lung disease, in particular cystic 
fibrosis and/or bronchiectasis
•    Patients who have received broad-spectrum antibiotic 
therapy for >7 days in the previous month
•    Patients who have recently been hospitalised (because of 
nosocomial colonisation).
4.8  Influenza pneumonia caused by influenza viruses type 
A or B can present as mild/moderate or as a severe ‘flu’ 
or ‘flu-like’ illness. Prognosis is worse if complicated by 
bacterial pneumonia. Avian influenza (influenza virus, type 
A (H5N1)) following close contact with infected poultry, 
and occasional human-to-human transmission, has been 
reported. Clinically the infection presents as a fulminant 
respiratory illness, followed by the development of adult 
respiratory distress syndrome (ARDS) and death in a large 
number of patients.
4.9  The possibility of infection with Mycobacterium tuberculosis 
should always be considered.  This infection is especially 
common in immunocompromised patients, such as those 
with concomitant HIV infection, and may present as an 
acute infection.  Tuberculosis should also be considered 
as a possible cause of pneumonia in immunocompetent 
individuals, particularly in those who are not responding 
to conventional antibiotic therapy. A number of antibiotics 
commonly used for CAP have antituberculosis activity, 
particularly the fluoroquinolones, and if used empirically 
for patients with suspected CAP who actually have 
tuberculosis, may complicate the diagnosis of tuberculosis 
as well as be associated with development of resistance of 
mycobacteria to that agent.
5. Establishing the diagnosis of 
pneumonia
A chest radiograph is advisable in all patients with pneumonia 
because it helps to:
•    confirm the diagnosis
•    delineate the extent of the consolidation
•    indicate the presence of underlying disorders
•    denote the presence of complications.
The chest radiographic features of CAP are not consistent 
or characteristic enough to suggest the most likely microbial 
cause.  However, infections with organisms such as P. jirovecii, 
in HIV-seropositive patients, tend to be associated with 
a diffuse pulmonary infiltrate, rather than with the more 
characteristic focal consolidation (lobar, segmental or sub-
segmental) of the common bacterial pathogens.  This may 
be helpful in suggesting the possibility of this opportunistic 
infection in immunocompromised cases.  However, in HIV-
seropositive patients bacterial infections may also present 
with a more diffuse infiltrate.  Pulmonary tuberculosis may 
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also sometimes present in this way, particularly in cases 
of disseminated disease, and especially in the setting of 
immunodeficiency.  An approach to the initial assessment and 
management of pneumonia in HIV-seropositive individuals, 
based on the chest radiographic appearance, is described more 
fully in Fig. 1.
6. Establishing the aetiological 
diagnosis 
6.1 I n general, the clinical features and/or other laboratory data 
are not sufficiently characteristic or consistent to suggest 
the likely microbial pathogen in patients with pneumonia 
and therefore cannot be used alone to guide initial therapy.
6.2  However, many HIV-seropositive patients who present with 
pneumonia have obvious clinical features of HIV infection 
(such as candidiasis and/or lymphadenopathy) together 
with a clinical presentation very suggestive of P. jirovecii 
infection: an infection with relatively acute or subacute 
onset, associated with tachypnoea, tachycardia, and signs 
of respiratory distress, such as cyanosis, alar flaring and use 
of accessory muscles, in association with diffuse pulmonary 
signs and infiltrates.  These features are most commonly 
seen in HIV-seropositive patients not receiving highly active 
antiretroviral therapy.
6.3  Even with extensive diagnostic testing, the causative 
organisms are identified in less than half of the cases.  An 
extensive initial diagnostic workup is not recommended.
6.4  In addition to the chest radiograph, the following 
investigations are recommended in the high-risk patient, in 
those with underlying co-morbid illness and in more severe 
infection:
•    Gram staining and culture of sputum or other respiratory 
tract secretions, as well as determination of the 
susceptibility of any cultured micro-organisms to the 
antibiotics commonly used and recommended in this 
guideline for patients with pneumonia.
•    Particularly in HIV-seropositive patients, additional 
specimens need to be submitted for investigation for M. 
tuberculosis (smear and/or culture) and for P. jirovecii 
(immunofluorescence).
•    Two sets of blood cultures should be performed in 
hospitalised cases.
•    Haematological and biochemical testing including full 
blood count and platelet count, serum electrolytes, 
urea, creatinine, protein, albumin, bilirubin and alanine 
transaminase should be performed in hospitalised cases. 
     These do not help determine aetiology but assist in 
the assessment of co-morbidity and influence decisions 
regarding hospitalisation, severity of illness and choice and 
dosages of antibiotics.
•    Thoracocentesis in patients with pleural effusions.
     Pleural fluid examination should include a white cell 
and differential count and measurement of the pH, protein, 
glucose and lactate dehydrogenase.  Gram staining and 
culture and Ziehl-Neelsen stain and culture for tuberculosis 
should be performed. Measurement of adenosine 
deaminase (ADA) may be helpful in excluding tuberculosis, 
if a low level is found. ADA levels are elevated in both 
parapneumonic effusions and tuberculosis and elevated 
ADA should only be considered strongly suggestive (but 
not confirmatory) of tuberculosis if there is an associated 
predominance of lymphocytes representing greater than 
50% of inflammatory cells in the pleural fluid differential 
count. 
•    Assessment of arterial oxygenation (pulse oximetry or blood 
gas analysis) in severely ill patients.
6.5  Pneumococcal and Legionella urinary antigen detection have 
good sensitivity and specificity but are expensive and are 
not recommended for routine use.
Suspect
P. jirovecii pneumonia (PCP)
and consider TB
CHEST RADIOGRAPH
Diffuse infiltrate Focal consolidation
Suspect usual
bacterial
pathogens
Sputum Gram
stain & culture
Sputum Gram
stain & culture
Sputum for
PCP & TB
Investigate Investigate
Blood cultures Blood cultures
Follow up
Treat empirically
as for PCP
Treat empirically
as for CAP
Response No response
Resolution
Additional investigations, e.g.
induced sputum for PCP
further investigations for TB
consider bronchoscopy
Fig. 1. An algorithmic approach to the evaluation of hospitalised HIV-
seropositive patients with community-acquired pneumonia, based on the 
chest radiographic features. This needs to be considered in conjunction 
with the clinical features. (Figure from Feldman C. Bacterial pneumonia 
in the HIV-seropositive patient. CME 2001; 19: 390-394, reproduced with 
permission.)
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6.6 Other investigations not routinely recommended include:
•    serological testing for ‘atypical pathogens’
•    additional tests for microbial antigens or antibodies
•    invasive diagnostic testing including bronchoscopy
•    investigative tools such as polymerase chain reaction 
techniques.
7.   Decision to hospitalise patients 
7.1  Not all patients with pneumonia require hospital 
admission, and it is not always easy to decide which 
patients can safely be managed at home.
7.2  An important consideration is the patient’s socio-economic 
status and home circumstances.
7.3 Additional factors are:
•    Age >65 years
•    Co-morbid illnesses:
     •    HIV infection
     •    chronic cardiorespiratory illness
     •    renal disease
     •    liver disease
     •    diabetes mellitus
•    Clinical features indicative of severe pneumonia:
     •    cyanosis
     •    confusion or decreased level of consciousness
     •    low blood pressure (<90 mmHg systolic, <60 mmHg 
diastolic)
     •    tachypnoea (>30 breaths/min)
•    Multilobar consolidation, bronchopneumonia, pleural 
effusion, cavitation, and rapidly expanding infiltrates
•    Complications of infection, for example empyema and lung 
abscess 
•    Laboratory parameters if undertaken: 
     •    hypoxaemia (<60 mmHg; <8 kPa) or <90% saturation
     •    white cell count of <4 or >30×109/l
     •    abnormal renal function (including urea >7 mmol/l)
     •    abnormal liver function (including albumin <30 g/l).
8. Severity of illness scores 
A number of severity of illness assessment tools have been 
developed to assist clinicians in assessing the severity of 
community-acquired pneumonia. Assessment of the severity of 
infection is important since it will determine appropriate site of 
care, microbiological work-up and empiric antibiotic treatment. 
One such scoring system is the CURB-65 score, which was 
derived from the British Thoracic Society rules. The scoring 
system uses five components, namely:
•    confusion 
•    urea >7 mmol/l 
•    respiratory rate >30 breaths/min 
•    low blood pressure (systolic <90 mmHg and diastolic <60 
mmHg, and 
•    age >65 years. 
Each parameter is assigned 1 point, if present. Patients 
with CAP and scores of 0 and 1 are thought to be mild and 
potentially suitable for management at home. Patients with 
scores of 2 are considered moderately ill and need to be 
observed in hospital initially. Patients with scores of >3 are 
thought to be severely ill, and need consideration for admission 
to a high-care or even intensive care unit. This scoring system 
has been recommended for use because of its simplicity, 
but also because its accuracy is similar to that of the more 
complicated scoring systems, such as the Pneumonia Severity 
Index. A variation of the CURB-65 is the CRB-65, which does 
not require the measurement of the urea level, making it more 
suitable for outpatient use, although it is less accurate. None of 
the scoring systems replace clinical assessment and important 
additional factors, such as socioeconomic deprivation and co-
morbidity, must influence the decision on hospitalisation and 
treatment. 
9. Suggested empiric antibiotic therapy 
Initial antibiotic therapy is empiric and recommendations 
offered are the result of careful consideration of all relevant 
local studies and several from abroad (see section 11 and 
Fig. 2). Different options are offered and individual choice of 
therapy is best guided by thorough knowledge of commonly 
encountered pathogens in the region or practice environment 
and a full appreciation of their usual susceptibility patterns.  
Significant differences have been noted, not only within the 
different geographical areas of South Africa, but also between 
the public and private sector.  Few of the recommended 
treatment regimens have been validated in prospective studies. 
A further recommendation is that since recent exposure to an 
antibiotic (in the past 3 months) is a risk factor for antibiotic 
resistance, particularly to that class of antibiotics, patients 
presenting with pneumonia should be asked about recent 
antibiotic exposure. If they have recently been exposed to a 
particular class of antibiotics, continued or repeated use of that 
class of antibiotics is not recommended or in the case of a beta-
lactam, an agent in that same class with a broader spectrum 
should be used. 
9.1 Patients treated at home
9.1.1 Young patients <65 years of age, without comorbid 
illness 
In young patients, below the age of 65 years and without 
comorbid illness, the treatment of choice is high-dose oral 
amoxicillin.
9.1.2 Elderly patients >65 years and/or adults with 
comorbidity including patients with HIV infection 
Alternative agents available for oral outpatient use, which are 
recommended for use in the elderly (>65 years), for patients 
with co-morbid illness, and for sicker patients, are amoxycillin-
Dec Part II.indd   1299 11/28/07   12:08:58 PM
1300
December 2007, Vol. 97, No. 12  SAMJ
GUIDELINE
Fig. 2. Algorithm for the management of community-acquired pneumonia in adults in South Africa. This should be read in conjunction with the text.
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clavulanate or selected oral cephalosporins (cefuroxime axetil 
or cefpodoxime). However, many of these patients may be 
better treated in hospital (see below).
Other alternative therapies:
•    Fluoroquinolones.  The fluoroquinolones with extended 
Gram-positive cover, i.e. moxifloxacin and gemifloxacin, 
are the preferred agents because of their superior 
microbiological efficacy against S. pneumoniae. Levofloxacin, 
which is now recommended at the higher dose (e.g. 750 
mg daily or 500 mg 12-hourly – see section 11.4), is also a 
suitable option. However, in order to limit the development 
of resistance, it is recommended that these agents are not 
used as routine first-line therapy, but rather are reserved 
for patients with severe allergy to standard beta-lactam 
agents, for known or suspected cases of infection with 
highly penicillin-resistant pneumococci or other resistant 
infections, and for patients in whom initial therapy with 
other antimicrobial agents has failed. These antibiotics also 
provide good cover, as monotherapy, for infections with the 
so-called ‘atypical pathogens’.
•    Macrolides/azalides. On the basis of current information on 
the mechanism, prevalence, and significance of macrolide/
azalide resistance in S. pneumoniae in South Africa, these 
agents are not routinely recommended as monotherapy for 
the treatment of CAP. The prevalence of resistance to these 
agents appears to be high in many areas, particularly in the 
private sector in South Africa. In areas known to have a low 
prevalence of macrolide resistance, such as in many of the 
public sectors, the continued use of macrolides/azalides 
as monotherapy in young, previously healthy adults, who 
have not recently been exposed to antibiotics, may still be 
acceptable. A thorough knowledge of common pathogens 
and their usual susceptibility pattern in one’s own area of 
practice is therefore essential. 
•    Telithromycin. This agent has in vitro activity against 
macrolide/azalide-resistant S. pneumoniae.  Like the 
fluoroquinolones, it is recommended that this agent is 
not used as routine first-line therapy, but reserved for 
patients with severe allergy to standard beta-lactam agents, 
for known or suspected cases of infection with highly 
penicillin- or macrolide-resistant pneumococci, and for cases 
in which initial therapy with other antimicrobial agents has 
failed.
•    Tetracycline/doxycycline. The considerable and increasing 
resistance of S. pneumoniae to tetracycline/doxycycline in 
South Africa limits its general use as monotherapy for CAP.
9.2 Hospitalised patients 
9.2.1 Young patients <65 years of age, with no comorbid 
illness 
The treatment of choice is high doses of parenteral penicillin or 
ampicillin or amoxycillin. 
Alternative therapy may be an intravenous anti-
pneumococcal fluoroquinolone, with the same considerations 
as described above.
9.2.2 Elderly patients >65 years and/or adults with 
comorbidity including patients with HIV infection 
The treatment of choice is either amoxycillin-clavulanate or 
a selected second-generation cephalosporin (cefuroxime) 
or a selected third-generation cephalosporin (ceftriaxone or 
cefotaxime) or ertapenem in specific circumstances (see 11.6 
below).  It is further recommended that these agents be given 
parenterally initially, at least until the temperature settles.  It 
is best to avoid aminoglycosides in the elderly.  An alternative 
choice is an intravenous anti-pneumococcal fluoroquinolone, 
particularly in the setting of severe beta-lactam allergy.
9.3 Additional therapy for both non-hospitalised 
and hospitalised cases
A macrolide, azalide, tetracycline or telithromycin is 
recommended on its own or as additional therapy for any 
patient being treated with a beta-lactam antibiotic in the case 
of suspected or proven infection with the so-called ‘atypical 
pathogens’.  While clinical features often do not allow the 
accurate differentiation of ‘atypical infections’ from the more 
common bacterial causes, it may be appropriate to add one 
of these agents to standard therapy in cases with atypical or 
unusual features, or in cases not responding to initial antibiotic 
treatment (see also 9.5 below – combination therapy).
9.4 Severely ill adults
The treatment of choice is a combination of parenteral 
amoxycillin-clavulanate or a parenteral second-generation 
cephalosporin (cefuroxime), or a third-generation 
cephalosporin (ceftriaxone or cefotaxime) or ertapenem 
in specific circumstances (see 11.6), together with an 
aminoglycoside (gentamicin or amikacin or tobramycin) and 
a macrolide (erythromycin, clarithromycin or azithromycin). 
The aminoglycoside is added initially because of the relatively 
high prevalence of CAP associated with aerobic Gram-negative 
bacilli documented previously in various intensive care unit 
studies in South Africa. The aminoglycoside may be stopped 
if a micro-organism other than a Gram-negative bacillus is 
isolated. 
Alternative treatment may include an anti-pneumococcal  
fluoroquinolone, particularly in the setting of severe beta-
lactam allergy. However, there are no data on whether 
these agents are adequately effective as monotherapy in 
critically ill cases and therefore at present, in this setting, it 
is recommended that if they are used it should be together 
with another antibiotic, such as a beta-lactam agent or an 
aminoglycoside. 
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9.5 Combination therapy 
There is emerging evidence that in patients with more severe 
pneumonia, combination antibiotic therapy, most commonly 
the addition of a macrolide agent to standard beta-lactam 
therapy, may be associated with a better outcome than 
monotherapy. Although the studies have been retrospective 
or purely observational in design the benefit in outcome has 
been shown particularly in sicker, hospitalised patients with 
pneumonia, including the sub-set of patients with bacteraemic 
pneumococcal infections. The current guideline recommends 
combination antibiotic therapy in severely ill patients with 
pneumonia (see section 8 above), admitted to hospital for 
intravenous antibiotic therapy, in line with most international 
pneumonia guidelines. 
9.6 Special clinical situations
9.6.1 Aspiration pneumonia
Aspiration may be a factor in the pathogenesis of all categories 
of CAP, but is a particular problem in the elderly and in 
the presence of conditions such as alcoholism, epilepsy and 
various neurological disorders, including cerebrovascular 
accident.  When macro-aspiration is suspected, antibiotic cover 
for anaerobic organisms must be provided.  Amoxycillin-
clavulanate alone affords adequate anaerobic cover, but oral or 
intravenous metronidazole may be added to any of the other 
regimens mentioned above.  An alternative is ertapenem in 
specific circumstances (see 11.6).
9.6.2 HIV-seropositive patients
Pneumonia, including infections with the common bacterial 
pathogens, is a common presenting symptom and is the 
AIDS-defining infection in a significant proportion of HIV-
seropositive patients.  It is therefore recommended that HIV 
testing be offered to all patients with pneumonia.  It is rarely 
necessary for this to be done at the time of presentation, 
and instead it should be offered when the patient has 
improved from the acute illness and has received appropriate 
counselling.  There is considerable evidence that prophylaxis 
with co-trimoxazole (recommended dosage is 2 single-strength 
tablets (trimethroprim 80 mg/sulfamethoxazole 400 mg) daily) 
in HIV-seropositive patients not only protects against P. jirovecii 
pneumonia, but also significantly reduces the incidence of 
pneumonia with usual bacterial pathogens. In the absence 
of antiretroviral therapy, co-trimoxazole prophylaxis reduces 
hospitalisation and mortality by 40 - 45% in association with 
the latter infection. 
In HIV-infected patients presenting acutely with bilateral 
pulmonary infiltrates suspected to be due to P. jirovecii, 
empirical therapy with co-trimoxazole should be given, either 
on its own or in addition to standard antibacterial therapy. 
The usual dose of co-trimoxazole in adults is 4 tablets (single-
strength) orally 6-hourly or 4 ampoules (trimethoprim 320 
mg and sulfamethoxazole 1 600 mg) intravenously 6-hourly. 
Hypoxic patients should also be given adjunctive therapy with 
corticosteroids. 
10. Initiation and duration of antibiotic 
therapy and switch to oral agents 
It is recommended that empiric therapy for patients with CAP 
is initiated as soon as possible. Some studies have suggested 
that in patients with pneumonia started on antibiotics within  
4 - 8 hours of presentation to hospital there is a better outcome. 
The optimal duration of parenteral antibiotic therapy and 
overall duration of antibiotic treatment is uncertain.  The usual 
recommendation is that antibiotics be given for 5 - 7 days for 
‘usual’ bacterial infections and for 14 days for severe Legionella 
infections. In patients initially on IV therapy ‘switch’ to oral 
agents may be made earlier in milder cases, particularly in 
those demonstrating a satisfactory clinical response in the first 
48 - 72 hours.  Switching from a parenteral to an oral antibiotic 
is made easier by the availability of agents such as amoxycillin-
clavulanate, cefuroxime, and moxifloxacin or levofloxacin 
which have both parenteral and oral forms, particularly 
because of their high systemic bioavailability.
11. Additional considerations in 
antibiotic therapy and dosages 
The current guideline is designed to ensure the 
recommendation of effective antibiotic cover for the most 
common micro-organisms involved in CAP.  However, 
cognisance also needs to be taken of the problem of increasing 
antibiotic resistance, both locally and internationally.  
Inappropriate selection of antibiotics, dosing schedules and 
length of treatment are the major reasons for emergence of 
resistance.  It is hoped that the appropriate use of antibiotics 
will reduce this phenomenon. The following notes regarding 
antibiotics are intended for guidance in their correct selection.
11.1 Penicillin and aminopenicillins
There is increasing resistance of S. pneumoniae to penicillin 
on the basis of alterations in the penicillin-binding proteins.  
Most of the current resistance is in the intermediate range.  For 
respiratory tract infections the recommended higher doses of 
parenteral penicillin and aminopenicillins will still provide 
more than adequate cover for these resistant pneumococcal 
infections. Risk factors for infection with beta-lactam-
resistant pneumococci in CAP for which such higher doses of 
intravenous and oral beta-lactams are mandatory include:
•   age >65 years
•   β-lactam therapy within past 3 months
•   alcoholism
•    immune suppression (including the use of corticosteroids)
•   multiple medical comorbidities
•   exposure to children in day care.
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Emerging resistance among H. influenzae isolates to the 
aminopenicillins, on the basis of beta-lactamase production, 
has been documented.  In situations where there is concern 
about beta-lactamase production by the infecting organisms, 
e.g. in patients with COPD colonised by such organisms, 
amoxycillin-clavulanate is the preferred antibiotic.
Parenteral
Penicillin G   2 - 4 million units 6-hourly
Ampicillin or amoxycillin 1 - 2 g 6-hourly
Amoxycillin-clavulanate 1.2 g 8-hourly.
Oral
Amoxycillin  1 g 8-hourly
Amoxycillin-clavulanate  1 g 12-hourly or 2 g sustained 
release (SR) 12-hourly (other 
dosing regimens, which may be 
less costly in some settings, such 
as the public hospitals, include 
625 mg tablets given 8-hourly 
or 375 mg tablets together with 
500 mg amoxycillin given 8-
hourly). Amoxycillin-clavulanate 
slow-release increases the time 
above the minimum inhibitory 
concentration (MIC) of amoxicillin, 
thus enhancing bacteriological 
efficacy in resistant pneumococcal 
strains. 
11.2 Macrolide or azalide
There is more than one mechanism of resistance, including 
both low-level (efflux-mediated) and high-level (ribosomal-
mediated) resistance. More recently isolates with both 
mechanisms of resistance have been described.  The 
commonest mechanisms in South Africa are associated 
with high-level resistance, which cannot be overcome by 
increasing the dose of the antibiotic.  These antibiotics may 
therefore be unsuitable as monotherapy for CAP in some 
parts of South Africa, particularly in the private sector.  Their 
use as alternative monotherapy may still be considered in 
areas where the prevalence of resistance is known to be low, 
such as in many parts of the state sector, especially in young, 
otherwise previously healthy patients who have not recently 
been exposed to antibiotics.  They are nevertheless the drugs 
of choice for ‘atypical infections’ and are recommended as an 
important part of combination therapy, as discussed above.
Parenteral
Erythromycin   4 - 5 mg/kg 6-hourly (usually 
administered as 1 g 6-hourly)
Clarithromycin  500 mg 12-hourly
Azithromycin   500 mg daily.
Oral
Erythromycin  500 mg 6-hourly
Clarithromycin  500 mg 12-hourly
Clarithromycin  1 g extended release (XL) daily
Azithromycin  500 mg daily.
11.3 Ketolides
Telithromycin is an antibacterial agent that belongs to a new 
chemical family – the ketolides. It has a broad spectrum of 
antibacterial activity, which encompasses penicillin-resistant 
and erythromycin-resistant S. pneumoniae, as well as ‘atypical’ 
micro-organisms. 
Oral
Telithromycin             800 mg daily.
11.4 Fluoroquinolones
The earlier drugs in this class such as ciprofloxacin offered 
activity against Gram-negative organisms, but relatively 
poor Gram-positive cover.  The newer agents have enhanced 
antipneumococcal activity.  The most active appear to be 
gemifloxacin and moxifloxacin followed by levofloxacin.  These 
agents provide a spectrum of activity against both typical 
and atypical organisms found in CAP.  In order to limit the 
development of resistance to these agents, it is suggested that 
their use be restricted to the indications discussed above.
Because of fluoroquinolone failures in this setting, it has been 
recommended that recent exposure of a patient to this class of 
antibiotic should be considered a contraindication to the use of 
another fluoroquinolone for the empiric treatment of CAP in 
the same individual.
Parenteral
Levofloxacin (high doses) 500 mg 12-hourly or 750 mg daily
Moxifloxacin  400 mg daily.
Oral
Gemifloxacin  320 mg daily
Levofloxacin (high doses) 500 mg 12-hourly or 750 mg daily
Moxifloxacin  400 mg daily.
11.5 Cephalosporins
The cephalosporin antibiotics recommended in the various 
sections of the guideline include second-generation agents, 
cefuroxime or cefpodoxime and the non-pseudomonal third-
generation agents, ceftriaxone and cefotaxime.  The advantage 
of the second-generation cephalosporins is that they retain 
Gram-positive cover and so still provide adequate cover 
(although they are not the antibiotic of choice) for S. aureus 
infections.  They may also be given orally or parenterally, 
which allows flexibility in their use and rapid-switch therapy.  
Owing to emerging resistance to cephalosporins, it is suggested 
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that these agents be given in high dosages.  The advantages 
of the third-generation cephalosporins include greater Gram-
negative cover and ease of use.  Cost considerations need to be 
taken into account in the final choice.
Parenteral (second- or third-generation cephalosporin)
Second generation
Cefuroxime   1.5 g 8-hourly.
Third generation
Ceftriaxone   2 g daily (up to a maximum of 4 g 
daily)
Cefotaxime   3 - 4 g daily in 2 - 4 
administrations.
Oral (second-generation cephalosporins)
Cefuroxime axetil  750 mg - 1 000 mg 12-hourly
Cefpodoxime               400 mg 12-hourly.
11.6 Ertapenem
Ertapenem is a broad-spectrum carbapenem, active against 
most common pathogens including pneumococci and 
anaerobes but not enterococci, non-fermenters (e.g. P. 
aeruginosa) or methicillin-resistant staphylococci. It remains 
active against most Enterobacteriaceae with extended-
spectrum beta-lactamases (ESBLs). In contrast to the other 
carbapenems it is administered once a day either intravenously 
or intramuscularly. In the case of CAP, this agent may be 
indicated in the following specific circumstances, as alternative 
to the standard therapies described above:
•    The elderly, especially high risk-cases with underlying 
comorbid illness and/or those living in long-term care 
facilities (LTCF), or in alcoholics where no risk factors for 
pseudomonal infections are present (see paragraph 4.7, risk 
factors for pseudomonal infections)
•    Aspiration pneumonia/suspected anaerobic infection/lung 
abscess, such as may occur in patients with neurological 
disorders or swallowing dysfunction
•    Cases known to be, or suspected of being, infected with 
pathogens resistant to standard antimicrobial agents but 
retaining susceptibility to ertapenem, especially in cases 
where Gram-negative pathogens are involved 
•    Patients who have failed standard first-line antibiotic 
therapy for CAP, particularly as part of directed antibiotic 
therapy based on the results of microbiological testing.
Parenteral (intravenous or intramuscular)
Ertapenem    1 g daily.
11.7 Aminoglycosides
These agents are recommended only as part of combination 
therapy for seriously ill patients in the intensive care unit, with 
suspected infections with K. pneumoniae.  Single daily dosing is 
recommended for the aminoglycosides, together with routine 
monitoring of trough serum drug levels.  Aminoglycosides 
may be discontinued if organisms other than Gram-negative 
bacteria are isolated. The maximum duration of therapy in any 
situation should not exceed 5 days. Aminoglycosides are best 
avoided, or used with extreme caution, in the elderly and in 
patients with renal impairment. 
Parenteral
Amikacin   15 mg/kg/day (up to 1.5 g daily)
Gentamicin   5 - 7 mg/kg/day (usually 320 mg 
daily)
Tobramycin   5 - 7 mg/kg/day (usually 320 mg 
daily).
11.8 Tetracycline
Doxycycline retains activity against H. influenzae.  There is 
considerable and increasing resistance of S. pneumoniae to this 
agent.  It may still be used as an add-on therapy for patients 
with infections with ‘atypical’ pathogens.
Oral
Doxycycline   200 mg stat followed by 100 mg 
bd.
12. Additional considerations in 
therapy 
Additional supportive measures that may be needed include 
bed rest, analgesia, attention to nutrition and hydration, 
support of cardiovascular and renal function and improvement 
of oxygenation.
13. Assessment of response to therapy 
13.1  With appropriate therapy, some improvement in the 
clinical features should be evident within 24 - 72 hours.  
In the elderly or in patients with comorbidity, resolution 
of the clinical features and the chest radiograph is 
considerably slower.
13.2  Additional considerations in patients who fail to respond 
to therapy include:
•    Use of inappropriate therapy (e.g. specific antibiotics for 
organisms such as S. aureus may be required)
•    Presence of unusual pathogens (e.g. opportunistic 
pathogens such as P. jirovecii)
•    Associated tuberculosis
•    Non-infective illness (e.g. pulmonary embolism, sarcoidosis 
and lung carcinoma) 
•    Complications of pneumonia (e.g. empyema, sepsis 
syndrome).
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Fig. 3. Algorithm for the diagnosis and initial management of lower respiratory tract infections in primary care – from the PALSA PLUS guideline 
developed for use in primary care clinics in South Africa. The initial step is recognition and grading of symptoms of lower respiratory tract infection. In 
patients with features of severe disease, urgent referral is preceded by a single dose of broad-spectrum antibiotic to cover common community-acquired 
pathogens. For those with milder presentations, amoxicillin (or erythromycin in penicillin-allergic patients) is recommended, but advice on smoking 
cessation and testing for HIV is offered to all. Sputum examination for tuberculosis is performed on those with suggestive symptoms.
•  New or 
increased 
sputum 
production
•  Fever
•  Pain on 
breathing or 
coughing
Consider:
•  LRTI (lower 
respiratory tract 
infection), 
including TB
Cough and/or diffi cult breathing < 2 weeks with:
SPUTUM PRODUCTION and/or FEVER and/or PAIN ON BREATHING OR COUGHING
(Severe disease excluded)
Consider:
Lower respiratory tract infection (LRTI)
e.g. Community-acquired pneumonia, acute bronchitis, infective COPD or chronic bronchitis exacerbations, or tuberculosis.1
COUGH AND/OR DIFFICULT BREATHING < 2 WEEKS
Assessment and initial management
INITIAL MANAGEMENT OF THE SEVERELY ILL CLIENT
Administer oxygen (40% face-mask oxygen, or at 4L/min via nasal 
prongs). If known COPD, administer 24-28% oxygen via face-mask.
Severe Acute 
Asthma/COPD
Exacerbation
MODERATE - MILD
While walking
May be anxious
Mild to normal
20-29 breaths/min
Blood streaking
NORMAL
None
Normal
Not obvious
14-19 breaths/min
None
•  Runny/blocked 
nose
•  Sore throat/ 
mouth
•  Pain or 
tenderness 
over sinuses
•  Ear problem
Consider:
•  URTI (upper 
respiratory tract 
infection)
•  Wheezing
•  Tight chest
If leg swelling, refer 
to doctor for diuretic
Consider:
•  Asthma/COPD 
exacerbationSevere Lower 
Respiratory Tract 
Infection
•  Ceftriaxone 1g IM or 
IV. If penicillin allergic, 
give erythromycin 
500mg orally stat.
•  Refer urgently with 
continuous oxygen.
Cardiac Failure
•  Refer urgently with 
continuous oxygen.
Wheezing/
tight chest
Temperature
≥ 38ºC
Leg swelling
1 Clients with pulmonary TB typically present with symptoms of more than 2 weeks duration. In a small percentage it may present with acute symptoms.
If suspected viral LRTI
•  Sputum production the same as usual in colour and volume.
If suspected bacterial LRTI
•  New or increased sputum production, or a change in colour to yellow, 
brown, or green.
or HIV client
Advise client to return for review after 2 days if at high risk of severe infection or symptoms worsen or do not improve.
Symptomatic treatment:
•  Bed rest
•  Provide pain and fever relief (paracetamol 1-2 tablets orally four times a day)
•  Regular fl uid intake
•  Research has shown that people are more likely to stop smoking if advised to do so by a health professional. Urge your clients to quit smoking.
In all clients:
•  Determine HIV status
•  Always look for TB symptoms. Exclude TB.
•  All HIV clients require antibiotics regardless of sputum production.
One or more of:
BREATHLESSNESS
MENTAL STATE
USE OF BREATHING MUSCLES
BREATH RATE
HAEMOPTYSIS
SEVERE
At rest or while talking
May be agitated or confused
Prominent
≥ 30 breaths/min
≥ Tablespoon of frank blood
and/or and/or
Reassure patient that antibiotics are not necessary.Prescribe amoxicillin 500mg orally three times a day for 5 days. 
If penicillin allergic: give erythromycin 500mg orally four times a day 
for 5 days.
If at high risk of severe infection:
(> 60 years; known severe lung, heart, liver disease, diabetes mellitus, 
and alcohol abuse)
•  Add ceftriaxone 1g IM/IV stat along with oral antibiotic.
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14. Influenza and pneumococcal 
vaccination guidelines 
Implementation of the South African National Guideline for 
the prevention of influenza and pneumococcal infections may 
assist in preventing CAP (see www.pulmonology.co.za). 
15. Disclaimer
This statement is published for educational purposes only. The 
recommendations are based on currently available scientific 
evidence together with the consensus opinion of the authors.
Annexure A: Working Group 
G M Ainslie, B Awotedu, E D Bateman A J Brink, C Feldman, 
M Greenblatt, E M Irusen, J R Joubert, L Krige, G Maartens, M J 
Mpe, M O Mzileni, J O’Brien, D Pansegrouw, O Perovic, M Plit, 
G Ras, G Richards, W L Sieling, C Smith, S S Visser, P Willcox, 
M Wong. 
Annexure B: Methodology 
A decision to revise the existing national clinical guidelines 
on the management of community-acquired pneumonia in 
adults was taken by the Executive Committee of the South 
African Thoracic Society. C Feldman, A J Brink and G A 
Richards undertook an initial redraft of the original document. 
The redrafted guideline was circulated to the members of the 
working group who still resided in South Africa. Additional 
members were added. The group was chosen to ensure 
adequate national representation, particularly from members 
of the South African Thoracic Society, the Critical Care Society 
of Southern Africa, and the Federation of Infectious Diseases 
Societies of Southern Africa. The redraft was then edited to 
include suggestions and recommendations from the working 
group. Any contentious issues were dealt with by circulation 
to the working group. The final document was sent to all 
members for final approval. 
Annexure C: Assessment and initial 
management of suspected pneumonia 
in primary care clinics 
A large proportion of patients with CAP in South Africa 
present to primary care clinics. Early recognition and treatment 
with an effective antimicrobial, particularly in those at risk 
because of concurrent disease (e.g. HIV infections), is likely to 
improve clinical outcomes and reduce mortality. Management 
and treatment is provided in accordance with diagnostic 
methods and essential drugs (specified in the Essential Drug 
List for Primary Care of the National Department of Health) 
at these facilities. Consequently, the approach in primary 
care clinics, though similar to the standard recommendations 
provided in this CAP guideline, differs in several respects.
Primary care clinic staff are provided with an integrated 
management plan for the diagnosis and management of 
patients with respiratory symptoms (PALSA PLUS – a 
local adaptation of the Practical Approach to Lung Health 
(PAL) developed by the World Health Organization). The 
management algorithm from the PALSA PLUS, which details 
the recognition of patients with lower respiratory tract 
infections, particularly those with severe disease who require 
immediate management including initiation of antibiotics, 
and referral, are presented in Fig. 3. The need to establish 
HIV status through testing in all patients with respiratory 
tract infections, and to look for symptoms of tuberculosis 
is emphasised. The selection of antibiotics (amoxicillin or 
erythromycin in penicillin-allergic patients, and a single dose of 
IM or IV ceftriaxone in those who are in a high risk category) 
is consistent with the EDL Standard Treatment Guidelines for 
these facilities. 
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